Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-(4-aminobenzyl) pyridin-2(1H)-one, with the molecular formula C13H12N2O, is a chemical compound derived from pyridine. It features a benzylamine group and an amide functional group, which contribute to its potential applications in the pharmaceutical and medicinal industries.

1017-42-1

Post Buying Request

1017-42-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1017-42-1 Usage

Uses

Used in Pharmaceutical and Medicinal Applications:
1-(4-aminobenzyl) pyridin-2(1H)-one is used as a building block for the synthesis of new drugs and pharmaceuticals. Its unique chemical structure allows for the development of various compounds with potential therapeutic uses.
Used in Research and Development:
1-(4-aminobenzyl) pyridin-2(1H)-one is also utilized in research and development for exploring its potential biological activities. Further investigation is required to fully understand its mechanism of action and possible applications in therapeutic treatments.

Check Digit Verification of cas no

The CAS Registry Mumber 1017-42-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,1 and 7 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1017-42:
(6*1)+(5*0)+(4*1)+(3*7)+(2*4)+(1*2)=41
41 % 10 = 1
So 1017-42-1 is a valid CAS Registry Number.

1017-42-1Downstream Products

1017-42-1Relevant articles and documents

A 2-pyridone modified zinc phthalocyanine with three-in-one multiple functions for photodynamic therapy

Li, Yanqing,Wang, Chongchong,Wei, Shaohua,Zhou, Lin

, p. 3127 - 3130 (2021)

A 2-pyridone modified zinc phthalocyanine (denoted ZnPc-PYR) achieves a one stone for three birds outcome in the photodynamic therapy (PDT) treatment of cancer. ZnPc-PYR can be excited by both 665 and 808 nm light to treat superficial and deep tumors, store and slowly release singlet oxygen (1O2) to improve its utilization and downregulate the HIF-1 (hypoxia-inducible factor 1) expression level to enhance the tumor cell's sensitivity to PDT treatment under hypoxic conditions.

Pyridone modified zinc phthalocyanine as well as preparation method and application thereof

-

Paragraph 0043; 0046-0047; 0050-0053, (2021/05/19)

The invention discloses pyridone-modified zinc phthalocyanine and a preparation method and application thereof. The pyridone-modified zinc phthalocyanine has the structural formula shown in the specification, novel zinc phthalocyanine is easy and convenie

THERAPEUTIC INHIBITORY COMPOUNDS

-

Page/Page column 45, (2015/07/16)

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1017-42-1